Evidence map›Paper›PMID 25088194›Full record

ArticleOncogene2015

Autocrine CSF1R signaling mediates switching between invasion and proliferation downstream of TGFβ in claudin-low breast tumor cells.

A Patsialou, Y Wang, J Pignatelli, X Chen, D Entenberg, M Oktay, J S Condeelis

Open access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Therapeutic, Clinicopathological, and Molecular Correlates ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

A PatsialouDepartment of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY, USA.
Y Wang1] Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY, USA [2] Gruss Lipper Biophotonics Center, Albert Einstein College of Medicine, Bronx, NY, USA.
J PignatelliDepartment of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY, USA.
X ChenDepartment of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY, USA.
D Entenberg1] Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY, USA [2] Gruss Lipper Biophotonics Center, Albert Einstein College of Medicine, Bronx, NY, USA.
M OktayDepartment of Pathology, Montefiore Medical Center, Bronx, NY, USA.
J S Condeelis1] Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY, USA [2] Gruss Lipper Biophotonics Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Albert Einstein College of Medicine · USMontefiore Medical Center · US

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2M
Tumor Progression and MetastasisP01CA100324 · NCI · YESHIVA UNIVERSITY · PI CONDEELIS, JOHN S · 2003 to 2018
$30.0M
In Vivo Multiphoton Based Imaging of Complex Cancer Cell BehaviorR01CA164468 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI VERKHUSHA, VLADISLAV · 2011 to 2015
$3.8M
Novel approach to study intravasation in primary human breast cancer cells(PQ24)R01CA170507 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CONDEELIS, JOHN S, GOSWAMI, SUMANTA · 2012 to 2015
$1.4M
NCI NIH HHS 5R01CA164468NCI NIH HHS P01 CA100324NCI NIH HHS P30 CA013330NCI NIH HHS R01 CA164468NCI NIH HHS R01 CA170507NCI NIH HHS R01CA170507
6 · The paper itself

Abstract

Patient data suggest that colony-stimulating factor-1 (CSF1) and its receptor (CSF1R) have critical roles during breast cancer progression. We have previously shown that in human breast tumors expressing both CSF1 and CSF1R, invasion in vivo is dependent both on a paracrine interaction with tumor-associated macrophages and an autocrine regulation of CSF1R in the tumor cells themselves. Although the role of the paracrine interaction between tumor cells and macrophages has been extensively studied, very little is known about the mechanism by which the autocrine CSF1R signaling contributes to tumor progression. We show here that breast cancer patients of the claudin-low subtype have significantly increased expression of CSF1R. Using a panel of breast cancer cell lines, we confirm that CSF1R expression is elevated and regulated by TGFβ specifically in claudin-low cell lines. Abrogation of autocrine CSF1R signaling in MDA-MB-231 xenografts (a claudin-low cell line) leads to increased tumor size by enhanced proliferation, but significantly reduced invasion, dissemination and metastasis. Indeed, we show that proliferation and invasion are oppositely regulated by CSF1R downstream of TGFβ only in claudin-low cell lines. Intravital multiphoton imaging revealed that inhibition of CSF1R in the tumor cells leads to decreased in vivo motility and a more cohesive morphology. We show that, both in vitro and in vivo, CSF1R inhibition results in a reversal of claudin-low marker expression by significant upregulation of luminal keratins and tight-junction proteins such as claudins. Finally, we show that artificial overexpression of claudins in MDA-MB-231 cells is sufficient to tip the cells from an invasive state to a proliferative state. Our results suggest that autocrine CSF1R signaling is essential in maintaining low claudin expression and that it mediates a switch between the proliferative and the invasive state in claudin-low tumor cells downstream of TGFβ.

Indexed as

AnimalsAutocrine CommunicationBreast NeoplasmsCell Line, TumorCell MovementCell ProliferationClaudinsDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMacrophage Colony-Stimulating FactorMCF-7 CellsMiceNeoplasm InvasivenessReceptor, Macrophage Colony-Stimulating FactorClaudinsMacrophage Colony-Stimulating FactorReceptor, Macrophage Colony-Stimulating FactorTransforming Growth Factor beta

Identifiers

PMID25088194
PMCPMC4317382
OpenAlexW2062755839

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.